Siponimod-d11

Siponimod-d11 (BAF-312-d11) is deuterium labeled Siponimod (HY-12355) . Siponimod is an orally active and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod is selective for S1P1 and S1P5 over S1P2, S1P3, and S1P4, with EC50s of 0.4, 0.98, >10000, >1000, and 750 nM, respectively. Siponimod can be used for multiple sclerosis (MS) research[1][2][3][4].

Product Specifications

CAS Number

[2104759-32-0]

Product Name Alternative

BAF-312-d11

UNSPSC

12352005

Target

Isotope-Labeled Compounds; LPL Receptor

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Others

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Solubility

10 mM in DMSO

Smiles

FC(F)(C1=C(C2([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C2([2H])[2H])C=CC(CO/N=C(C3=CC(CC)=C(C=C3)CN4CC(C4)C(O)=O)\C)=C1)F

Molecular Formula

C29H24D11F3N2O3

Molecular Weight

527.66

References & Citations

[1]Gergely P, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012 Nov;167 (5) :1035-47.|[2]Behrangi N, et al. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019 Jan 7;8 (1) :24.|[3]McGinley M, et al. Prospects of siponimod in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2018 Jul 17;11:1756286418788013.|[4]Pan S, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4 (3) :333-7.